Sökning: WFRF:(Axelsson Fredrik) >
Human Epidermal Gro...
Human Epidermal Growth Factor Receptor 2 (HER2) PET Imaging of HER2-Low Breast Cancer with [ 68 Ga]Ga-ABY-025 : Results from a Pilot Study
-
- Altena, Renske (författare)
- Karolinska Institutet,Karolinska Univ Hosp, Karolinska Comprehens Canc Ctr, Solna, Sweden.;Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden.
-
- af Buren, Siri (författare)
- Karolinska Institutet,Karolinska Inst, Dept Clin Sci Intervent & Technol CLINTEC, Div Radiol, Stockholm, Sweden.;Karolinska Univ Hosp, Funct Unit Nucl Med, Med Radiat Phys & Nucl Med, Huddinge, Sweden.
-
- Blomgren, August (författare)
- Karolinska Univ Hosp, Funct Unit Nucl Med, Med Radiat Phys & Nucl Med, Huddinge, Sweden.
-
visa fler...
-
- Karlsson, Emelie (författare)
- Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden.
-
- Tzortzakakis, Antonios (författare)
- Karolinska Institutet,Karolinska Inst, Dept Clin Sci Intervent & Technol CLINTEC, Div Radiol, Stockholm, Sweden.;Karolinska Univ Hosp, Funct Unit Nucl Med, Med Radiat Phys & Nucl Med, Huddinge, Sweden.
-
- Brun, Nikolai (författare)
- Affibody AB, Solna, Sweden.
-
- Moein, Mohammad M. (författare)
- Karolinska Univ Hosp, Dept Radiopharm, Solna, Sweden.
-
- Jussing, Emma (författare)
- Karolinska Institutet,Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden.;Karolinska Univ Hosp, Dept Radiopharm, Solna, Sweden.
-
- Frejd, Fredrik (författare)
- Uppsala universitet,Cancerprecisionsmedicin,Affibody AB, Solna, Sweden.
-
- Bergh, Jonas (författare)
- Karolinska Institutet,Karolinska Univ Hosp, Karolinska Comprehens Canc Ctr, Solna, Sweden.;Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden.
-
- Tran, Thuy A. (författare)
- Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden.;Karolinska Univ Hosp, Dept Radiopharm, Solna, Sweden.
-
- Hartman, Johan (författare)
- Karolinska Institutet,Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden.;Karolinska Univ Hosp, Dept Pathol & Canc Diagnost, Solna, Sweden.
-
- Axelsson, Rimma (författare)
- Karolinska Institutet,Karolinska Univ Hosp, Funct Unit Nucl Med, Med Radiat Phys & Nucl Med, Huddinge, Sweden.;Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden.
-
visa färre...
-
Karolinska Institutet Karolinska Univ Hosp, Karolinska Comprehens Canc Ctr, Solna, Sweden;Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden. (creator_code:org_t)
- Society of Nuclear Medicine and Molecular Imaging, 2024
- 2024
- Engelska.
-
Ingår i: Journal of Nuclear Medicine. - : Society of Nuclear Medicine and Molecular Imaging. - 0161-5505 .- 1535-5667. ; 65:5, s. 700-707
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.2...
-
http://kipublication...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Patients with HER2-low metastatic breast cancer (mBC), defined as an immunohistochemistry (IHC) score of 1+ or 2+ without HER2 gene amplification, may benefit from HER2 antibody-drug conjugates. Identifying suitable candidates is a clinical challenge because of spatial and temporal heterogeneity in HER2 expression and discrepancies in pathologic reporting. We aimed to investigate the feasibility and safety of HER2-specific PET imaging with [ 68 Ga]Ga-ABY-025 for visualization of HER2-low mBC.Methods: A prospective pilot study was done with 10 patients who had HER2-low mBC, as part of a phase 2 basket imaging study with [ 68 Ga]Ga-ABY-025 in HER2-expressing solid tumors. Patients were recruited at the Breast Clinic at the Karolinska University Hospital, Stockholm, Sweden. PET/CT images were acquired 3 h after injection of 200 MBq of [ 68 Ga]Ga-ABY-025. The SUV max was used to quantify tracer uptake. Ultrasound-guided tumor biopsies were guided by results from the HER2 PET. The main outcome-the safety and feasibility of HER2 PET in patients with HER2low mBC, measured the occurrence of possible procedure -related adverse events.Results: Ten patients with HER2-low mBC underwent [ 68 Ga]Ga-ABY-025 PET/CT with paired tumor biopsies. No adverse events occurred. In all patients, [ 68 Ga]Ga-ABY-025-avid lesions with substantial intra- and interindividual heterogeneity in tracer uptake were noted. In 8 of 10 patients with ABY-025-avid lesions, the HER2low status of the corresponding lesions was confirmed by IHC or in situ hybridization. Two patients had an IHC score of 0 in the tumor biopsies:1 in a cutaneous lesion with a low SUV max and 1 in a liver metastasis with a high SUV max but a "cold" core.Conclusion: The visualization of HER2-low mBC with [ 68 Ga]Ga-ABY-025 PET/CT was feasible and safe. Areas of tracer uptake showed varying levels of HER2 expression on IHC. The observed intra- and interindividual heterogeneity in [ 68 Ga]Ga-ABY-025 uptake suggested that HER2 PET might be used as a tool for the noninvasive assessment of disease heterogeneity and has the potential to identify patients in whom HER2-targeted drugs can have a clinical benefit.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Radiologi och bildbehandling (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Radiology, Nuclear Medicine and Medical Imaging (hsv//eng)
Nyckelord
- HER2 PET
- HER2-low breast cancer
- [ 68 Ga]Ga-ABY-025
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Altena, Renske
-
af Buren, Siri
-
Blomgren, August
-
Karlsson, Emelie
-
Tzortzakakis, An ...
-
Brun, Nikolai
-
visa fler...
-
Moein, Mohammad ...
-
Jussing, Emma
-
Frejd, Fredrik
-
Bergh, Jonas
-
Tran, Thuy A.
-
Hartman, Johan
-
Axelsson, Rimma
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Radiologi och bi ...
- Artiklar i publikationen
-
Journal of Nucle ...
- Av lärosätet
-
Uppsala universitet
-
Karolinska Institutet